Medicare Coverage for Wegovy, Zepbound, and Foundayo in 2026
Learn who may qualify for the Medicare GLP-1 Bridge, which Wegovy, Zepbound, and Foundayo products are included, and how the $50 copay works.
WEIGHT MANAGEMENTACCESS, COST, & CARE
Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare
9/4/202611 min read
Medicare Coverage for Wegovy, Zepbound, and Foundayo in 2026
Medicare historically excluded prescription medications used solely for weight loss. That changed on July 1, 2026, when the temporary Medicare GLP-1 Bridge began.
Eligible Medicare beneficiaries may now receive certain formulations of Wegovy® (semaglutide), Zepbound® (tirzepatide), or Foundayo™ (orforglipron) for weight management with a $50 monthly copayment.
Coverage is not automatic. The beneficiary must have a qualifying type of Medicare Part D drug coverage, be at least 18 years old, meet the Bridge’s clinical criteria, receive an included product for weight management, and obtain prior authorization.
Learn More: How to Check Insurance Coverage for Weight-Loss Medication
The Bridge criteria are narrower than the FDA indications for chronic weight management. A person may be medically eligible for an obesity medication but not qualify for payment through this Medicare program.
Which GLP-1 Medications Does the Medicare Bridge Include?
Current covered products are:
Wegovy: Injections and tablets
Zepbound: KwikPen only
Foundayo: Tablets
Zepbound single-dose pens and single-dose vials are not included. CMS may update the eligible product list during the program.
The Bridge began July 1, 2026, and is scheduled to continue through December 31, 2027.
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a temporary demonstration administered by the Centers for Medicare & Medicaid Services.
It provides eligible Medicare Part D beneficiaries access to specified medications when they are prescribed to reduce excess body weight or maintain weight reduction as part of an ongoing lifestyle program involving nutrition and physical activity.
The Bridge operates outside the normal Part D payment flow. A national central processor manages claims and prior authorization. Access therefore does not depend on an individual Part D sponsor choosing to participate.
This separate payment structure also explains why the $50 copayment does not count toward the Part D deductible or annual true out-of-pocket costs.
Which Types of Medicare Drug Coverage Qualify?
The Bridge is available with certain types of Medicare drug coverage, including:
A standalone Medicare Prescription Drug Plan
A qualifying Medicare Advantage plan with drug coverage
A Special Needs Plan
An employer or union group waiver plan
The Limited Income Newly Eligible Transition program
Original Medicare Parts A and B without Part D drug coverage are not sufficient.
Some special plan types are not eligible, including certain private fee-for-service plans, cost plans, health care prepayment plans, and PACE organizations. Medicare can confirm whether a specific plan type qualifies.
Who May Qualify for the Medicare GLP-1 Bridge?
The beneficiary must be at least 18 years old and meet one of the following clinical pathways based on status when GLP-1 therapy began.
Learn More: Who Qualifies for Prescription Weight-Loss Medication?
BMI of 35 or higher
A BMI of at least 35 at treatment initiation may satisfy the clinical pathway without one of the additional diagnoses listed below.
BMI of 30 or higher with a qualifying condition
A BMI of at least 30 at treatment initiation must be accompanied by at least one of the following:
Heart failure with preserved ejection fraction, also called diastolic heart failure
Uncontrolled hypertension as defined by the Bridge criteria
Chronic kidney disease at stage 3a or higher
BMI of 27 or higher with a qualifying condition
A BMI of at least 27 at treatment initiation must be accompanied by at least one of the following:
Prediabetes
Previous myocardial infarction
Previous stroke
Symptomatic peripheral artery disease
People below a BMI of 27 at treatment initiation do not meet the current BMI pathways.
These are Medicare Bridge payment criteria. They do not fully describe FDA eligibility, clinical appropriateness, or prescribing requirements.
Learn More: Does BCBS Oklahoma Cover Weight-Loss Medication?
What If the Current BMI Is Lower Than the Starting BMI?
CMS uses BMI at the time GLP-1 therapy began rather than requiring the beneficiary to regain weight or meet the same BMI on the date of prior authorization.
When current BMI is lower because treatment has been effective, the prescriber may attest to the qualifying pretreatment BMI if the clinical record supports it.
Relevant documentation may include earlier office notes, recorded height and weight, prior prescriptions, pharmacy history, previous insurance authorizations, or records from another clinic.
Availability and sufficiency of historical documentation are determined during the authorization process.
Who Is Not Eligible for the Bridge?
Current exclusions include people who:
Do not have a qualifying type of Medicare Part D coverage
Are younger than 18
Do not meet one of the BMI and clinical pathways
Already receive a GLP-1 drug through their Part D plan
Are requesting a product or formulation not included in the Bridge
Are receiving the medication for an indication that should be processed through standard Part D
Are not using the medication as part of an ongoing nutrition and physical-activity program
The Medicare site also directs people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying fatty liver disease to regular Part D because GLP-1 treatment for those indications may be coverable through the standard benefit.
The exact diagnosis matters. A general history of fatty liver, for example, is not necessarily the same as the FDA-approved Wegovy indication for noncirrhotic MASH with moderate-to-advanced fibrosis.
Why Some Diagnoses Are Routed Through Part D
The Bridge is designed for GLP-1 use specifically to reduce excess body weight or maintain weight reduction.
Standard Part D may cover certain GLP-1 medications for other FDA-approved or medically accepted indications, including type 2 diabetes, qualifying cardiovascular-risk reduction, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH with qualifying fibrosis.
Routing through Part D does not guarantee coverage. The product must match the treated diagnosis, and the Part D plan may apply its own formulary, prior-authorization, step-therapy, and pharmacy rules.
The diagnosis and intended treatment indication must be documented accurately. A clinician cannot submit an unsupported diagnosis to obtain coverage.
Learn More: Zepbound sleep-apnea coverage coming soon
Wegovy Medicare Coverage in 2026
Wegovy contains semaglutide and is available as a weekly injection and a daily tablet.
Through the Medicare GLP-1 Bridge
Both Wegovy injections and Wegovy tablets are included for eligible beneficiaries when prescribed for weight management. The Bridge copayment is $50 for a monthly supply.
Through standard Part D
Wegovy may be processed through Part D when prescribed for a qualifying indication covered under the standard benefit.
Current FDA-approved uses include chronic weight reduction, cardiovascular-event risk reduction in certain adults with established cardiovascular disease and overweight or obesity, and treatment of noncirrhotic MASH with moderate-to-advanced fibrosis. The injectable formulation also has a pediatric weight-management indication.
Part D coverage remains plan-specific. An FDA-approved indication does not guarantee placement on every formulary or approval without restrictions.
REad More: Wegovy cardiovascular, MASH Coming soon
Zepbound Medicare Coverage in 2026
Zepbound contains tirzepatide and is administered once weekly.
Through the Medicare GLP-1 Bridge
Only the Zepbound KwikPen is included. The Bridge does not cover Zepbound single-dose pens or single-dose vials.
Compatible pen needles are separate supplies and are not included in the Bridge medication copayment.
Through standard Part D
Zepbound is FDA-approved for chronic weight reduction and for moderate-to-severe obstructive sleep apnea in adults with obesity.
When Zepbound is prescribed to treat qualifying obstructive sleep apnea, the claim is directed to the Part D plan rather than the weight-management Bridge. The Part D plan may require records such as a sleep study and documentation of disease severity.
Learn More: Wegovy and Zepbound Self-Pay Prices: What Patients Need to Know in 2026
Foundayo Medicare Coverage in 2026
Foundayo contains orforglipron, an oral nonpeptide GLP-1 receptor agonist approved in 2026 as a daily tablet for chronic weight management.
All current Foundayo tablet formulations are included in the Bridge for beneficiaries who meet program requirements.
Foundayo’s current FDA indication is chronic weight management. Medicare payment for that use is therefore generally processed through the Bridge rather than ordinary Part D. This may change if FDA indications or Medicare policies change.
What Does the $50 Copayment Cover?
Eligible beneficiaries pay $50 for a monthly supply of an included medication.
Because the Bridge operates outside the standard Part D payment flow, the $50 payment:
Does not apply to the Part D deductible
Does not count toward the annual Part D out-of-pocket limit
Is not reduced by the Part D low-income subsidy
Is not eligible for the Medicare Prescription Payment Plan
Cannot be reduced with coupons or other discount programs
The medication copayment does not include unrelated costs such as clinical visits, laboratory testing, pen needles, or other supplies.
Can a Manufacturer Coupon Reduce the Bridge Copay?
No. CMS states that the Bridge will not coordinate benefits with other payers and that coupons or discount programs may not be applied to Bridge claims.
Commercial manufacturer savings programs also commonly exclude people enrolled in Medicare and other government-funded insurance.
Learn More: Does Aetna Cover Medical Weight-Loss Treatment in Oklahoma?
Prior Authorization Is Required
The prescriber must certify that the beneficiary meets the program requirements, that the medication is being prescribed for weight management, and that it is being used with ongoing nutrition and physical-activity intervention.
CMS states that the prescriber attests under penalty of perjury that the submitted information is accurate and complete. The Bridge may verify information using Medicare claims and other records.
This requirement prevents unsupported diagnoses, altered historical information, or inaccurate attestations from being used to obtain eligibility.
How the Medicare Bridge Prior-Authorization Process Works
CMS describes the following sequence:
The prescriber sends a prescription for an included medication to the pharmacy.
The pharmacy submits the claim to the Medicare GLP-1 Bridge.
The claim establishes the beneficiary in the Bridge system and triggers prior authorization.
The pharmacy sends the request to the prescriber electronically or by fax.
The prescriber submits the completed authorization.
The Bridge reviews the information and sends the decision to the prescriber and beneficiary.
If approved, the pharmacy resubmits or processes the claim with the $50 copayment.
CMS advises prescribers not to submit the prior authorization before the pharmacy has sent the initial Bridge claim. An early submission may return a “patient not found” error because the system has not yet established the beneficiary’s claim.
A Part D denial is not required before a claim can be routed to the Bridge.
How Long Does Prior Authorization Take?
The pharmacy typically transmits the authorization request to the prescriber within 24 to 72 hours after the Bridge claim is submitted.
After the completed prior authorization reaches the Bridge, CMS states that the approval or denial is sent within 72 hours.
Delays may occur when Medicare identification is missing, the claim is sent to the wrong payer, the formulation is not included, clinical information is incomplete, or historical BMI documentation is unavailable.
If the prescriber has not received the request after 72 hours, CMS permits use of the Bridge fax form.
How Long Does Bridge Approval Last?
An approved authorization is valid through December 31, 2027, including refills and dose changes, as long as the beneficiary remains eligible and stays on the same covered GLP-1 drug.
Switching from one covered GLP-1 medication to another generally requires a new authorization.
A beneficiary may lose Bridge eligibility after approval if a GLP-1 is later paid through Part D or if enrollment changes to an ineligible plan type.
Can a Bridge Denial Be Appealed?
The Medicare GLP-1 Bridge does not have a standard appeal process.
CMS permits the prescriber to resubmit the prior-authorization form if incorrect information was entered or if updated or additional information is available.
This differs from ordinary Part D coverage decisions, which generally include formal appeal rights. Repeating the same accurate information does not change a denial based on failure to meet the Bridge criteria.
What About People Who Started Treatment Before July 2026?
Starting a GLP-1 before the Bridge began does not automatically prevent eligibility.
The program looks at BMI and qualifying conditions when GLP-1 therapy began. Treatment may have started before July 1, 2026, before Medicare enrollment, through commercial insurance, through self-pay, or with another healthcare clinic.
Historical records may be needed to establish the starting BMI and treatment date. Lack of documentation can make verification more difficult.
What If Part D Already Pays for a GLP-1?
A beneficiary who already receives a GLP-1 through Part D is not eligible to move that medication to the Bridge solely to obtain the $50 copayment.
Standard Part D costs may be affected by the deductible, tier, copay or coinsurance, Extra Help, the annual out-of-pocket limit, and the Medicare Prescription Payment Plan.
The beneficiary does not freely choose between Part D and the Bridge. The treated indication, prior Part D use, plan type, and program criteria determine the appropriate pathway.
Cardiovascular Disease and Bridge Eligibility
Some Bridge criteria overlap with Wegovy’s FDA-approved cardiovascular-risk-reduction indication. Previous myocardial infarction, previous stroke, and symptomatic peripheral artery disease can support a Bridge pathway when the prescription is for weight management.
CMS distinguishes pathways by the intended treatment indication. If Wegovy is prescribed to reduce major adverse cardiovascular events, the claim goes to the Part D plan. If it is prescribed for weight management and the beneficiary meets Bridge requirements, the Bridge may be the appropriate pathway.
The clinical indication must be recorded accurately even when the patient has overlapping diagnoses.
Obstructive Sleep Apnea and Zepbound
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
When Zepbound is prescribed for that indication, coverage is considered through regular Part D rather than the Bridge. A Part D plan may require prior authorization, obesity documentation, sleep-study results, and evidence of moderate-to-severe disease.
A diagnosis of sleep apnea does not automatically guarantee Part D approval.
MASH and Wegovy
Wegovy has an FDA-approved indication for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis.
When prescribed for that qualifying liver indication, Wegovy is processed through Part D rather than the weight-management Bridge.
“Fatty liver disease” includes a broad range of findings. Mildly elevated liver enzymes or a general history of fatty liver does not necessarily establish noncirrhotic MASH with the required fibrosis stage.
If the Bridge Criteria Are Not Met
Failure to qualify for the Bridge is a coverage determination under one temporary program. It does not, by itself, determine whether obesity treatment is medically appropriate.
Other financial or treatment pathways may include standard Part D coverage for a different FDA-approved indication, another medication on the plan formulary, official manufacturer self-pay programs, lower-cost FDA-approved obesity medications, or weight-management care without a GLP-1.
The medically appropriate option depends on the clinical evaluation. Medicare beneficiaries generally cannot use commercial manufacturer copay cards.
Learn More:: How to Check Insurance Coverage for Weight-Loss Medication
Information Commonly Needed for Bridge Review
The authorization process may require:
Active Medicare Part D and Medicare identification information
Current height and weight
Height, weight, and BMI from the start of GLP-1 therapy
Treatment-start date and previous prescription records
Documentation supporting a qualifying condition
The exact medication and formulation requested
A pharmacy able to process Bridge claims
The exact supporting records depend on the pathway used. CMS and the prescriber determine whether the available documentation is sufficient.
The Bottom Line
The Medicare GLP-1 Bridge currently provides eligible Medicare Part D beneficiaries access to Wegovy injections or tablets, Foundayo tablets, or Zepbound KwikPen for $50 per month.
Coverage is not available to every Medicare beneficiary with overweight or obesity. Eligibility depends on qualifying drug coverage, age, the BMI and medical conditions present when GLP-1 therapy began, the treated indication, the selected product, and successful prior authorization.
The Bridge is scheduled to continue through December 31, 2027. Approved authorizations generally remain valid through that date for refills and dose changes unless the medication changes or eligibility is lost.
Medicare policies, covered products, and operational rules can change. Current information from Medicare and CMS takes priority over general online guidance.
Optima Vida Healthcare can evaluate clinical appropriateness, document available eligibility information, and complete prior-authorization requests when supported by the medical record. OVH cannot guarantee Medicare approval or submit unsupported information.
Sarina Helton, MSN, APRN, FNP-C, CAE-OM
Founder, Optima Vida Healthcare
Ready to Learn More About Medical Weight Management?
Learn More; How to Get a GLP-1 Prescription in Oklahoma
At Optima Vida Healthcare, weight-management evaluations consider health history, previous treatments, medication response, side effects, goals, and long-term needs. Treatment may include lifestyle support, laboratory evaluation, and medication when clinically appropriate.
Start Your Weight-Management Evaluation →
Visit www.ovhmed.com for more information.
The visit fee covers medical evaluation and related clinical services only. Medication, pharmacy, laboratory, and other third-party costs are separate unless specifically stated. A prescription, prior authorization, or Medicare approval is not guaranteed.
Learn More: Medical Weight-Loss Clinic in Owasso: What We Offer
Disclaimer
This article is for general educational purposes only. It does not provide individualized medical, Medicare, insurance, legal, or financial advice and does not determine personal eligibility. Program rules, covered products, dates, and costs can change. Current requirements should be verified directly with Medicare, CMS, the prescription plan, pharmacy, and prescribing clinician.
Sources
Medicare Wegovy, Zepbound & Foundayo Coverage in 2026
Learn who may qualify for the Medicare GLP-1 Bridge, which Wegovy, Zepbound, and Foundayo products are included, and how the $50 copay works.
/medicare-coverage-wegovy-zepbound-foundayo-2026
Medicare GLP-1 coverage 2026
Medicare Wegovy coverage, Medicare Zepbound coverage, Medicare Foundayo coverage, Medicare GLP-1 Bridge, Medicare weight-loss drugs, $50 GLP-1 Medicare
Contact
Optima Vida Healthcare, LLC
Telehealth medical services
support@ovhmed.com
© 2026 Optima Vida Healthcare, LLC. All rights reserved.